Martin Samuel Bates bought CLDX
January 2, 2024 · Form 4 insider transaction
Martin Samuel Bates bought 10,750 shares of Celldex Therapeutics, Inc. at $2.78 per share, a transaction worth $29.9K. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
10,750
Price
$2.78
Total value
$29.9K
InsiderMartin Samuel Bates
RoleOfficer
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateJanuary 2, 2024
Filing dateJanuary 4, 2024
Shares owned after35,128
OwnershipDirect
10b5-1 planNo
AmendedNo